Or a deal separated among VLU,DFU, Ocular and special skin disease should be structured. This is just to not kill the technology. I see too often innovation ending in the shelves. As you know patents in biotechnology allow many changes to the platform when needed.
Who has the key to understsnd, has everything.
book, page-154
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
